High materiality8/10
Scribe Therapeutics initiated with an Outperform at Leerink Partners
Why it may matterVerify against the original reporting
Outperform initiation; notable upside for SCTX.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Leerink Partners initiates SCTX with Outperform; target $37; current price $21.19; upside potential.
- Leerink Partners initiates SCTX with Outperform; target $37; current price $21.19; upside potential.
Key facts
- 01
Target: $37
- 02
Posted price: $21.19
- 03
Analyst firm: Leerink Partners
- 04
Analyst: David Risinger
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.